

Thomas J Kipps

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2425261/thomas-j-kipps-publications-by-citations.pdf>

Version: 2023-05-30

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

578
papers

43,242
citations

89
h-index

204
g-index

592
ext. papers

47,999
ext. citations

5.4
avg, IF

6.93
L-index

#	Paper	IF	Citations
578	Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 15524-9	11.1	4008
577	miR-15 and miR-16 induce apoptosis by targeting BCL2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 13944-9	11.1	2884
576	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. <i>Blood</i> , 2008 , 111, 5446-56	2.1	2513
575	A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2005 , 353, 1793-801	57.2	2038
574	Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2014 , 370, 997-1007	57.2	1295
573	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 311-22	57.2	1149
572	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 213-23	57.2	1145
571	MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 11755-60	11.1	1105
570	CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. <i>Blood</i> , 2006 , 107, 1761-7	2.1	952
569	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 2425-37	57.2	930
568	Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2001 , 194, 1639-47	16.2	884
567	ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2004 , 351, 893-901	57.2	756
566	MiR-15a and miR-16-1 cluster functions in human leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 5166-71	11.1	633
565	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. <i>Journal of Clinical Oncology</i> , 2012 , 30, 488-96	2.1	621
564	Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. <i>Cancer Cell</i> , 2007 , 12, 215-29	23.1	593
563	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018 , 131, 2745-2760	2.1	587
562	Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. <i>Blood</i> , 2000 , 96, 2655-2663	2.1	583

561	Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. <i>Cancer Research</i> , 2006 , 66, 11590-3	9.6	529
560	Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1749-55	2.1	481
559	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 826-833	2.1	432
558	Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2018 , 378, 1107-1120	57.2	441
557	Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 4609-14	2.1	406
556	Chronic Lymphocytic Leukemia B Cells Express Functional CXCR4 Chemokine Receptors That Mediate Spontaneous Migration Beneath Bone Marrow Stromal Cells. <i>Blood</i> , 1999 , 94, 3658-3667	2.1	391
555	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2019 , 380, 2225-2236	57.2	354
554	Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 3118-23	11.1	338
553	Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. <i>Cell</i> , 2007 , 129, 879-90	54.5	303
552	CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. <i>Blood</i> , 2000 , 96, 2917-2924	2.1	295
551	Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 13253-7	11.1	291
550	Reprogramming of miRNA networks in cancer and leukemia. <i>Genome Research</i> , 2010 , 20, 589-99	9.4	280
549	The CD5 B cell. <i>Advances in Immunology</i> , 1989 , 47, 117-85	5.3	264
548	Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3047-52	11.1	247
547	Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005 , 106, 1824-30	2.1	246
546	Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 113, 299-305	2.1	238
545	Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. <i>Blood</i> , 2005 , 106, 1012-20	2.1	231
544	ATM Mutations in Cancer: Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1781-91	5.8	230

543	Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. <i>Oncogene</i> , 2003 , 22, 8093-101	8.9	225
542	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 59-67	26.8	219
541	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016 , 128, 195-203	2.1	217
540	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncology, The</i> , 2017 , 18, 230-240	20.9	223
539	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. <i>Blood</i> , 2014 , 123, 1810-7	2.1	218
538	Chronic lymphocytic leukaemia. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 16096	49	215
537	ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 105, 2036-41	2.1	204
536	Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. <i>Blood</i> , 2004 , 104, 2499-504	2.1	198
535	Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 99, 1030-7	2.1	196
534	DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2016 , 48, 253-64	35.2	190
533	Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. <i>Blood</i> , 2002 , 100, 1795-1801	2.1	187
532	BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. <i>Blood</i> , 2007 , 109, 703-10	2.1	177
531	Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. <i>Nature Medicine</i> , 1997 , 3, 984-9	49.3	170
530	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020 , 34, 787-798	10.3	172
529	NOTCH1 mutations in CLL associated with trisomy 12. <i>Blood</i> , 2012 , 119, 329-31	2.1	166
528	Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 269-277	2.1	170
527	Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2820-2	2.1	160
526	ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. <i>PLoS ONE</i> , 2012 , 7, e31127	3.6	156

525	Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. <i>Journal of Immunology</i> , 2005 , 174, 864-70	5.2	156
524	The soluble CD40 ligand sCD154 in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 1999 , 104, 947-55	15.3	154
523	Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 12210-5	11.1	150
522	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017 , 102, 1796-1805	6.4	150
521	The triterpenoid CDDO induces apoptosis in refractory CLL B cells. <i>Blood</i> , 2002 , 100, 2965-72	2.1	145
520	Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. <i>PLoS Computational Biology</i> , 2015 , 11, e1004105	4.8	143
519	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 1353-1363	6.9	138
518	Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). <i>Chemistry and Biology</i> , 2004 , 11, 389-95		135
517	Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. <i>Journal of Clinical Investigation</i> , 2001 , 107, 305-15	15.3	134
516	An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. <i>British Journal of Haematology</i> , 2008 , 142, 802-7	4.4	130
515	TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. <i>Journal of Immunology</i> , 2000 , 165, 5084-96	5.2	127
514	Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 5071-6	11.1	127
513	Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 17266-71	11.1	127
512	MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 124, 546-54	2.1	129
511	The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. <i>American Journal of Pathology</i> , 2012 , 181, 1903-10	5.6	127
510	A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2826-33 ^{1.8}		123
509	Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2008 , 26, 196-203	2.1	120
508	Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. <i>Leukemia and Lymphoma</i> , 2002 , 43, 461-6	1.8	119

507	Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. <i>Journal of Clinical Investigation</i> , 2016 , 126, 585-98	15.3	116
506	Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 107, 859-61	2.1	118
505	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2016 , 30, 750-763	23.1	117
504	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019 , 133, 2031-2042	20.4	114
503	Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. <i>Cancer Discovery</i> , 2014 , 4, 348-61	23.4	113
502	ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 2685-92	2.1	112
501	miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. <i>Blood</i> , 2014 , 124, 84-95	2.1	107
500	Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. <i>Cancer Research</i> , 2013 , 73, 3649-60	9.6	106
499	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 117, 6450-8	2.1	108
498	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 996-1000	6.2	112
497	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1391-1402	2.1	103
496	Familial cancer associated with a polymorphism in ARLTS1. <i>New England Journal of Medicine</i> , 2005 , 352, 1667-76	57.2	104
495	Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2483-91	2.1	101
494	CCL3 (MIP-1 β) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 117, 1662-9	2.1	98
493	Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , 2007 , 13, 4448-55	12.3	96
492	Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2136-42	1.8	89
491	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Blood</i> , 2017 , 129, 2702-2705	2.1	92
490	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , 2019 , 134, 111-122	2.1	93

489	Lack of allelic exclusion in B cell chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 1997 , 185, 1435-45	16.2	90
488	Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. <i>Leukemia Research</i> , 2005 , 29, 1253-7	2.1	89
487	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1188-1200	20.9	84
486	Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 19643-8	11.1	80
485	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018 , 103, 1502-1510	6.4	79
484	Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. <i>Blood</i> , 2002 , 100, 1795-801	2.1	79
483	Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15 Suppl, S167-9	0.7	77
482	MicroRNAs play a role in neoplasia. <i>Blood</i> , 2007 , 109, 5071-5072	2.1	77
481	TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3877-85	2.1	77
480	Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 19532-7	11.1	76
479	Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 115, 489-95	2.1	77
478	13q14 deletions in CLL involve cooperating tumor suppressors. <i>Blood</i> , 2010 , 115, 3916-22	2.1	74
477	Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 3854-9	11.1	75
476	Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. <i>PLoS ONE</i> , 2009 , 4, e8294	3.6	71
475	Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. <i>Cell Stem Cell</i> , 2018 , 22, 951-959.e3	17.2	71
474	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 2931-2940	2.1	71
473	Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. <i>Blood</i> , 2009 , 113, 3168-71	2.1	70
472	Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. <i>Cellular Immunology</i> , 1995 , 161, 226-35	4.2	67

471	ROR1 can interact with TCL1 and enhance leukemogenesis in E μ TCL1 transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 793-8	11.1	66
470	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4042-4054	2.1	66
469	Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. <i>Carcinogenesis</i> , 2010 , 31, 208-15	4.4	65
468	Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. <i>Cancer Cell</i> , 2009 , 16, 161-71	23.1	63
467	Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. <i>Cancer</i> , 2004 , 101, 999-1008	6.2	63
466	Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. <i>Blood</i> , 2015 , 125, 2779-85	2.1	63
465	Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 6127-32	11.1	63
464	The pathogenesis of chronic lymphocytic leukemia. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2014 , 9, 103-18	32.8	61
463	Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. <i>Blood</i> , 2008 , 111, 5101-8	2.1	61
462	Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 1370-1377	11.1	61
461	Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. <i>Cell Reports</i> , 2018 , 22, 1875-1888	10.3	57
460	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019 , 3, 1799-1807	7.5	59
459	Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 127, 79-86	2.1	59
458	Chronic lymphocytic leukaemia. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17008	49	61
457	Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. <i>Journal of Immunology</i> , 2001 , 166, 95-102	5.2	59
456	Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. <i>PLoS ONE</i> , 2010 , 5, e11716	3.6	58
455	Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. <i>Haematologica</i> , 2015 , 100, 945-54	6.4	55
454	Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. <i>Blood</i> , 2016 , 128, 1609-13	2.1	56

453	Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias. <i>Oncotarget</i> , 2016 , 7, 54174-54182	3.2	57
452	ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2011 , 35, 1390-4	2.1	56
451	B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 18956-60	11.1	56
450	A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 254-254	2.1	55
449	Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. <i>Blood</i> , 2005 , 106, 1742-8	2.1	55
448	AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1650-60	5.8	53
447	Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. <i>Blood</i> , 2014 , 123, 4101-10	2.1	54
446	Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. <i>Oncotarget</i> , 2016 , 7, 2809-22	3.2	54
445	Second Interim Analysis of a Phase 3 Study of Idelalisib (Zydelig [®]) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. <i>Blood</i> , 2014 , 124, 330-330	2.1	54
444	Dielectrophoretic isolation and detection of cfDNA nanoparticulate biomarkers and virus from blood. <i>Electrophoresis</i> , 2013 , 34, 1076-84	3.4	53
443	Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. <i>Blood</i> , 2011 , 117, 882-9	2.1	51
442	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 124, 42-8	2.1	50
441	MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007 , 139, 709-16	4.4	50
440	Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005 , 105, 3193-8	2.1	50
439	The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. <i>British Journal of Haematology</i> , 2016 , 173, 105-13	4.4	50
438	Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1644-52		48
437	An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes i blood group specificity on normal human B cells. <i>European Journal of Immunology</i> , 1992 , 22, 1781-8	5.8	48
436	Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2555-60	11.1	47

435	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. <i>British Journal of Haematology</i> , 2017 , 178, 286-291	4.4	47
434	Novel immune-based treatment strategies for chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6325-32	2.1	47
433	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. <i>Nature</i> , 2019 , 570, 474-479	47.5	47
432	Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. <i>Clinical Chemistry</i> , 2014 , 60, 500-9	5.3	45
431	MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1836-9	1.8	45
430	TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 2169-74	11.1	43
429	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 133, 2765-2775	2.1	43
428	Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. <i>Electrophoresis</i> , 2014 , 35, 1828-36	3.4	41
427	Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. <i>Blood</i> , 2009 , 114, 4469-76	2.1	42
426	Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. <i>Cancer Gene Therapy</i> , 2000 , 7, 1051-9	5.2	42
425	Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2015 , 39, 495-500	2.1	41
424	Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015 , 6, 1884-8	3.2	42
423	Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. <i>Blood</i> , 2012 , 119, 2293-301	2.1	40
422	Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. <i>Cancer Genetics and Cytogenetics</i> , 2010 , 203, 134-40		40
421	Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. <i>Blood</i> , 2008 , 111, 3137-44	2.1	39
420	Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). <i>Molecular Medicine</i> , 2012 , 18, 19-28 ⁹		37
419	Tcl1 interacts with Atm and enhances NF- κ B activation in hematologic malignancies. <i>Blood</i> , 2012 , 119, 180-7	2.1	38
418	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. <i>British Journal of Haematology</i> , 2016 , 175, 892-903	4.4	36

417	A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. <i>Cancer Cell</i> , 2019 , 35, 283-296.e5	23.1	37
416	Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. <i>PLoS ONE</i> , 2015 , 10, e0128151	3.6	37
415	Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. <i>Cancer Research</i> , 2012 , 72, 2937-48	9.6	35
414	Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 404-10	2.1	35
413	Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. <i>EBioMedicine</i> , 2015 , 2, 572-82	8.6	33
412	Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. <i>Cancer Genetics and Cytogenetics</i> , 2010 , 203, 161-8		33
411	Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study. <i>Blood</i> , 2015 , 126, 830-830	2.1	33
410	ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7015-7015	2.1	33
409	Transfer of human chronic lymphocytic leukemia to mice with severe combined immune deficiency. <i>Leukemia Research</i> , 1992 , 16, 1013-23	2.1	33
408	Isolation of heavy chain class switch variants of a monoclonal anti-DC1 hybridoma cell line: effective conversion of noncytotoxic IgG1 antibodies to cytotoxic IgG2 antibodies. <i>Human Immunology</i> , 1983 , 8, 141-51	2.2	33
407	Quaking and miR-155 interactions in inflammation and leukemogenesis. <i>Oncotarget</i> , 2015 , 6, 24599-6103.2		31
406	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 234-234	2.1	32
405	The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 415-24	4	32
404	The V4-34 encoded anti-i autoantibodies recognize a large subset of human and mouse B-cells. <i>Blood Cells, Molecules, and Diseases</i> , 1996 , 22, 126-38	2.1	31
403	Wnt5a Signaling in Normal and Cancer Stem Cells. <i>Stem Cells International</i> , 2017 , 2017, 5295286	4.8	31
402	Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 4322-7	11.1	30
401	dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 10731-10736	11.1	31
400	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2019 , 134, 35-35	2.1	33

399	Reduction in mitochondrial membrane potential is an early event in Fas-independent CTL-mediated apoptosis. <i>Cellular Immunology</i> , 1999 , 195, 43-52	4.2	30
398	The Philadelphia (Ph) chromosome in leukemia. II. Variant Ph translocations in acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1985 , 14, 11-21		30
397	Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. <i>Human Gene Therapy</i> , 2003 , 14, 849-60	4.7	29
396	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014 , 124, 325-325	2.1	28
395	Cellular immune therapy for chronic lymphocytic leukemia. <i>Blood</i> , 2007 , 110, 2811-8	2.1	29
394	Chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 1998 , 5, 244-53	3.2	28
393	Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. <i>Blood</i> , 2018 , 132, 170-178	2.1	27
392	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 12-20	6.4	29
391	hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents. <i>ACS Chemical Biology</i> , 2017 , 12, 444-455	4.8	25
390	Stabilized cyclopropane analogs of the splicing inhibitor FD-895. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 6576-82	7.9	25
389	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 1630-1630	2.1	23
388	Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 24252-24258	11.1	24
387	Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. <i>Experimental Hematology</i> , 2007 , 35, 434-42	1	24
386	Anti-B cell autoantibodies encoded by VH 4-21 genes in human fetal spleen do not require in vivo somatic selection. <i>European Journal of Immunology</i> , 1994 , 24, 2941-9	5.8	23
385	CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. <i>Cancer Research</i> , 2003 , 63, 4128-35	9.6	23
384	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 715-722.e6	0.7	22
383	Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib.	2.1	22
382	Immunoglobulin V gene expression in CD5 B-cell malignancies. <i>Annals of the New York Academy of Sciences</i> , 1992 , 651, 373-83	6.3	22

381	Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF- κ B to repress autocrine STAT3 activation in chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 134, 1084-1094	2.1	21
380	A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients \geq 5 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2014 , 124, 1986-1986	2.1	21
379	Chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 1997 , 4, 268-76	3.2	20
378	Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. <i>Blood</i> , 2006 , 112, 326-328	2.1	18
377	Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 712-716	12.9	19
376	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018 , 93, 1402-1410	6.9	19
375	Structure and function of the hematopoietic cancer niche focus on chronic lymphocytic leukemia. <i>Frontiers in Bioscience - Scholar</i> , 2012 , S4, 61-73	2.1	19
374	Analysis of immunoglobulin VH gene repertoire by an anchored PCR-ELISA. <i>Annals of the New York Academy of Sciences</i> , 1995 , 764, 463-73	6.3	19
373	Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009 , 33, 368-76	2.1	19
372	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014 , 124, 3331-3331	2.1	17
371	Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. <i>Vaccine</i> , 2001 , 19, 2181-9	3.9	19
370	Origin of high-grade lymphomas in Richter syndrome. <i>Leukemia and Lymphoma</i> , 1995 , 18, 367-72	1.8	19
369	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019 , 94, 554-562	6.9	18
368	Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2019 , 33, 653-661	10.3	18
367	Ibrutinib for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 1594-5	57.2	17
366	Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1414-1427	6.4	17
365	Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 971-4	2.1	18
364	Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. <i>Cancer Genetics and Cytogenetics</i> , 2010 , 203, 141-8		19

363	The long noncoding RNA, <i>trRNA</i> , decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017 , 8, 25942-25954	3.2	18
362	Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 2450-2450	2.1	17
361	Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). <i>Blood</i> , 2015 , 126, 494-494	2.1	18
360	Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results.. <i>Blood</i> , 2006 , 108, 32-32	2.1	17
359	Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients \geq 5 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2014 , 124, 1994-1994	2.1	16
358	Advances in classification and therapy of indolent B-cell malignancies. <i>Seminars in Oncology</i> , 2002 , 29, 98-104	5.3	16
357	Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2019 , 3, 1167-1174	7.5	15
356	Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2011 , 117, 116-24	6.2	16
355	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020 , 97, 106432	2.1	16
354	Immunobiology of chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 2003 , 10, 312-8	3.2	17
353	Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. <i>International Journal of Hematologic Oncology</i> , 2016 , 5, 27-35	0.9	15
352	Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 134, 688-698	2.1	16
351	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1291-9	1.8	15
350	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2021 , 106, 2364-2373	6.4	16
349	HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. <i>Molecular Therapy</i> , 2002 , 6, 455-63	11.4	15
348	CD154 gene therapy for human B-cell malignancies. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1062, 51-60	6.3	16
347	Selectivity in Small Molecule Splicing Modulation. <i>ACS Chemical Biology</i> , 2016 , 11, 2716-2723	4.8	14
346	NF-B-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. <i>Cell Death and Differentiation</i> , 2020 , 27, 2206-2216	12.3	15

345	Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.. <i>Blood</i> , 2009 , 114, 207-207	2.1	14
344	Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2017 , 129, 181-181	2.1	14
343	In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. <i>Clinical Cancer Research</i> , 2003 , 9, 2166-72	12.3	14
342	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 185-217	6.4	14
341	Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. <i>Frontiers in Bioscience - Scholar</i> , 2012 , 4, 61-73	2.1	14
340	Targeted Therapy in Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 378-385	2.1	12
339	Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. <i>Blood</i> , 2012 , 120, 1687-90	2.1	13
338	A general process for the development of peptide-based immunoassays for monoclonal antibodies. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 919-25	3.4	13
337	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019 , 134, 355-355	2.1	13
336	A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005 , 106, 446-446	2.1	13
335	A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens.. <i>Blood</i> , 2007 , 110, 3119-3119	2.1	13
334	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. <i>Haematologica</i> , 2015 , 100, e311-4	6.4	12
333	Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2011 , 129, 1162-9	7.3	12
332	miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. <i>Blood</i> , 2021 , 137, 2481-2494	2.1	12
331	Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. <i>Oncotarget</i> , 2018 , 9, 24731-24736	3.2	12
330	An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009 , 114, 883-883	2.1	12
329	Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3K In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation. <i>Blood</i> , 2013 , 122, 1632-1632	2.1	12
328	Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies. <i>Blood</i> , 2013 , 122, 1810-1810	2.1	12

327	Transgenic expression of a human polyreactive Ig expressed in chronic lymphocytic leukemia generates memory-type B cells that respond to nonspecific immune activation. <i>Journal of Immunology</i> , 2004 , 172, 2092-9	5.2	12
326	Expression of Ig- κ (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. <i>Blood</i> , 2000 , 95, 2725-2727	2.1	12
325	Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. <i>Blood</i> , 2013 , 121, 351-9	2.1	12
324	Rituximab in chronic lymphocytic leukemia. <i>Advances in Therapy</i> , 2011 , 28, 534-54	4	11
323	Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. <i>British Journal of Haematology</i> , 2010 , 151, 336-45	4.4	11
322	Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7510-7510	2.1	11
321	Gene therapy and active immune therapy of hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 557-68	4	11
320	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3853-3865	2.1	12
319	A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2013 , 98, 964-70	6.4	10
318	Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C. <i>ACS Chemical Biology</i> , 2010 , 5, 287-99	4.8	10
317	IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. <i>PLoS ONE</i> , 2013 , 8, e65203	3.6	10
316	The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group. <i>Blood</i> , 2008 , 112, 753-753	2.1	9
315	Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014 , 124, 4687-4687	2.1	10
314	ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7013-7013	2.1	8
313	Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. <i>British Journal of Haematology</i> , 2000 , 108, 641-52	4.4	10
312	Genetic mapping of the BGL idiotypic marker within the Igh-V region. <i>Immunogenetics</i> , 1979 , 9, 297-302	3.1	10
311	Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. <i>International Journal of Clinical and Experimental Pathology</i> , 2010 , 3, 448-57	1.3	10
310	A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3461-3469	1.8	9

309	SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019 , 184, 605-615	4.4	9
308	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1000-1005	1.8	9
307	Chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 1999 , 6, 253-61	3.2	9
306	Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006 , 108, 2837-2837	2.1	9
305	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. <i>Blood</i> , 2014 , 124, 1990-1990	2.1	8
304	Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7083-7083	2.1	9
303	Immune and cell therapy of hematologic malignancies. <i>International Journal of Hematology</i> , 2002 , 76 Suppl 1, 269-73	2.2	9
302	Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 133, 2651-2663	2.1	8
301	Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 9407-21	6.1	8
300	Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. <i>Oncogene</i> , 2020 , 39, 2550-2567	8.9	8
299	Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2011 , 118, 3904-3904	2.1	8
298	Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase 1b Galton Trial (GAO4779g). <i>Blood</i> , 2013 , 122, 523-523	2.1	8
297	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). <i>Blood</i> , 2016 , 128, 2054-2054	2.1	8
296	CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. <i>Blood</i> , 2000 , 95, 3853-3858	2.1	4
295	Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7012-7012	2.1	8
294	HNRNPL Restrains Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2019 , 11,	6.3	7
293	The Cell Surface Receptor CD44: NMR-Based Characterization of Putative Ligands. <i>ChemMedChem</i> , 2016 , 11, 1097-106	3.5	7
292	Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1835-8	1.8	7

291	Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. <i>Haematologica</i> , 2020 , 105, e22-e25	6.4	7
290	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. <i>Science Translational Medicine</i> , 2020 , 12,	16.9	7
289	Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism. <i>Leukemia</i> , 2021 , 35, 1621-1630	10.3	7
288	Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment.. <i>Nature Cancer</i> , 2021 , 2, 758-772	14.7	9
287	Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004 , 104, 2503-2503	2.1	8
286	Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.. <i>Blood</i> , 2005 , 106, 707-707	2.1	7
285	Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis. <i>Npj Breast Cancer</i> , 2019 , 5, 35	7.5	6
284	Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. <i>Blood</i> , 2019 , 133, 990-992	2.1	6
283	Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2011 , 86, 405-411	3.6	6
282	Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2021 , 102, 106520	2.1	6
281	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018 , 132, 184-184	2.1	6
280	Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL. <i>Blood</i> , 2019 , 134, 3036-3036	2.1	6
279	An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2008 , 112, 3177-3177	2.1	6
278	Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 921-921	2.1	6
277	Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 190-190	2.1	6
276	11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. <i>Blood</i> , 2016 , 128, 2042-2042	2.1	6
275	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016 , 128, 4383-4383	2.1	6
274	Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 557-68	2.1	7

273	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019 , 186, 184-188	4.4	5
272	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021 , 2, 54-69	5.7	6
271	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. <i>Cancer Cell</i> , 2021 , 39, 380-393.e8	23.1	5
270	Response: Letters regarding Blood. 2008;111:5446-5456 by Hanson et al and Mulligan et al. <i>Blood</i> , 2009 , 113, 6497-6498	2.1	5
269	Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab. <i>Blood</i> , 2018 , 132, 183-183	2.1	5
268	A Multi-Center and Multi-National Program To Assess the Clinical Accuracy of the Molecular Subclassification of Leukemia by Gene Expression Profiling.. <i>Blood</i> , 2005 , 106, 757-757	2.1	5
267	Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL. <i>Blood</i> , 2010 , 116, 58-58	2.1	5
266	Cirmtuzumab Vedotin (UC-961ADC3), An Anti-ROR1-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment For ROR1-Positive Leukemia and Solid Tumors. <i>Blood</i> , 2013 , 122, 1637-1637	2.1	5
265	Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. <i>British Journal of Haematology</i> , 2002 , 118, 506-13	4.4	5
264	Survival adjusting for crossover: phase 3 study of ibrutinib . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2018 , 103, e249-e251	6.4	4
263	An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2819-25	1.8	4
262	Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. <i>Human Gene Therapy</i> , 2015 , 26, 14-25	4.7	4
261	A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1878-80	1.8	4
260	Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 15-29	4	5
259	Increased aldehyde dehydrogenase activity in high-risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 400-2	1.8	4
258	Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2011 , 35, 965-7	2.1	4
257	Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia. <i>Journal of Immunology</i> , 2011 , 186, 6338-44	5.2	4
256	Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1). <i>Blood</i> , 2018 , 132, 1862-1862	2.1	4

255	Restricted Expression of the Orphan Tyrosine Kinase Receptor ROR1 in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004 , 104, 772-772	2.1	4
254	Lenalidomide Abrogates the Protective Influence of Nurse-Like Cells on Primary Chronic Lymphocytic Leukemia Cells In Vitro.. <i>Blood</i> , 2007 , 110, 3116-3116	2.1	4
253	IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy.. <i>Blood</i> , 2007 , 110, 753-753	2.1	4
252	Association Between the Proficiency of B-Cell Receptor Signaling and the Relative Expression Levels of ZAP-70, SHIP-1, and Mir-155 in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008 , 112, 3155-3155	2.1	4
251	Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.. <i>Blood</i> , 2009 , 114, 3433-3433	2.1	4
250	Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010 , 116, 2455-2455	2.1	4
249	BMS-936564 (Anti-CXCR4 Antibody) Induces Specific Leukemia Cell Mobilization and Objective Clinical Responses In CLL Patients Treated Under a Phase I Clinical Trial. <i>Blood</i> , 2013 , 122, 4190-4190	2.1	3
248	A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions. <i>Blood</i> , 2016 , 128, 2048-2048	2.1	4
247	Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7011-7011	2.1	4
246	Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA7008-LBA7008	2.1	4
245	Expression of an Ig VH gene, 51p1, is proportional to its germline gene copy number. <i>Annals of the New York Academy of Sciences</i> , 1997 , 815, 478-80	6.3	4
244	Advances in classification and therapy of indolent B-cell malignancies. <i>Seminars in Oncology</i> , 2002 , 29, 98-104	5.3	4
243	Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. <i>British Journal of Haematology</i> , 2018 , 180, 597-600	4.4	3
242	Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. <i>Targeted Oncology</i> , 2019 , 14, 551-561	4.8	3
241	Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 114	21.8	3
240	Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease. <i>Journal of Human Genetics</i> , 2011 , 56, 676-81 ^{4.1}		3
239	A cross-trial comparison of single-agent ibrutinib chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020 , 105, e164-e168	6.4	2
238	Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. <i>Clinical Cancer Research</i> , 2021 , 27, 4690-4695	12.3	3

237	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. <i>Cancer Discovery</i> , 2021 ,	23.4	3
236	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. <i>Blood</i> , 2018 , 132, 5565-5565	2.1	3
235	AT-101, a Pan-Inhibitor of Bcl-2 Family Anti-Apoptotic Proteins Antagonizes the Protective Effect Conferred by Nurse-like Cells on Primary Chronic Lymphocytic Leukemia (CLL) Cells.. <i>Blood</i> , 2006 , 108, 2100-2100	2.1	3
234	Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations. <i>Blood</i> , 2011 , 118, 288-288	2.1	3
233	Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. <i>Blood</i> , 2011 , 118, 291-291	2.1	3
232	MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study. <i>Blood</i> , 2012 , 120, 3677-3677	2.1	3
231	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. <i>Blood</i> , 2012 , 120, 3923-3923	2.1	3
230	TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). <i>Blood</i> , 2013 , 122, 1638-1638	2.1	3
229	A Phase Ib/II Study of Combined Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016 , 128, 2051-2051 ¹	2.1	3
228	Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 968-968	2.1	3
227	Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7099-7099	2.1	3
226	Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. <i>Leukemia and Lymphoma</i> , 2017 , 58, 348-356	1.8	2
225	Exploring the pathways to chronic lymphocytic leukemia. <i>Blood</i> , 2021 , 138, 827-835	2.1	3
224	First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. <i>Blood</i> , 2018 , 132, 185-185	2.1	2
223	Anti-CD20 Antibody Rituximab and Anti-CD23 Antibody IDEC-152 Induce Apoptosis of Malignant B-Cells in Combination with Chemical Antagonists of XIAP.. <i>Blood</i> , 2004 , 104, 1401-1401	2.1	2
222	AT 101, an Inhibitor of Bcl-2 Family Members Is Cytotoxic to a Heterogeneous Group of CLL Samples and Synergistic with Rituximab.. <i>Blood</i> , 2005 , 106, 2979-2979	2.1	2
221	Membrane-Stable, Humanized CD154 Gene Therapy for Patients with CLL.. <i>Blood</i> , 2006 , 108, 2104-2104	2.1	2
220	Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006 , 108, 2778-2778	2.1	2

219	Expression of MicroRNA (miR) miR-15a/miR-16-1 Downregulates Expression of BCL-2 Protein in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006 , 108, 2796-2796	2.1	2
218	Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients (pts) with CLL.. <i>Blood</i> , 2006 , 108, 2839-2839	2.1	2
217	Dasatinib Induces Apoptosis in Chronic Lymphocytic Leukemia and Enhances the Activity of Rituximab and Fludarabine.. <i>Blood</i> , 2007 , 110, 1116-1116	2.1	2
216	Percentage of Smudge Cells on Blood Smear Predicts Prognosis in Chronic Lymphocytic Leukemia: A Multicenter Study.. <i>Blood</i> , 2007 , 110, 745-745	2.1	2
215	Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort. <i>Blood</i> , 2008 , 112, 3125-3125	2.1	2
214	Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS). <i>Blood</i> , 2010 , 116, 923-923	2.1	2
213	A Highly Selective Anti-ROR1 Monoclonal Antibody Inhibits Human Acute Myeloid Leukemia CD34+ Cell Survival and Self-Renewal.. <i>Blood</i> , 2012 , 120, 2560-2560	2.1	2
212	Fd-895 and Pladienolide B Inhibit mRNA Splicing and Induce Apoptosis in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 3890-3890	2.1	2
211	Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). <i>Blood</i> , 2012 , 120, 3925-3925	2.1	2
210	Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 3926-3926	2.1	2
209	Combined ROR1 and CD160 Detection For Improved Minimal Residual Disease In Patients With Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 2572-2572	2.1	2
208	Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect ² CLL Registry. <i>Blood</i> , 2014 , 124, 3338-3338	2.1	2
207	Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium Labeling Predicts Time to Initial Treatment of Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014 , 124, 829-829	2.1	2
206	Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts. <i>Blood</i> , 2015 , 126, 1736-1736	2.1	2
205	The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 2911-2911	2.1	2
204	Targeting the CXCR4-CXCL12 Pathway Using an Anti-CXCR4 IgG1 Antibody (PF-06747143) in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 4162-4162	2.1	2
203	Wnt5a Induces ROR1 to Complex with HS1, Which Undergoes Tyrosine Phosphorylation and Contributes to Planar-Cell-Polarity Migration in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 301-301	2.1	2
202	Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA7008-LBA7008	2.1	2

201	Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS7120-TPS7120	2.1	2
200	Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7013-7013	2.1	2
199	Antigen receptor signaling in CLL: the line dead?. <i>Blood</i> , 2003 , 101, 788-788	2.1	2
198	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.. <i>Blood</i> , 2022 ,	2.1	2
197	Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers 2022 , 1,		2
196	Epac1, an anti-apoptotic protein, is up-regulated in chronic lymphocytic leukemic B-cells. <i>FASEB Journal</i> , 2011 , 25, 1090.1	0.9	1
195	SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 321-325	0.7	1
194	Interview: Chronic lymphocytic leukemia: treating an incurable disease. <i>International Journal of Hematologic Oncology</i> , 2013 , 2, 203-205	0.9	1
193	Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Results From a Randomized, Multicenter, International, Two-Dose, Parallel-Group Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, E33-E34	0.7	1
192	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2021 ,	10.3	1
191	Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7556-7556	2.1	1
190	Response: Defining response criteria in CLL patients treated in clinical research trials. <i>Blood</i> , 2010 , 116, 1817-1818	2.1	1
189	Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial. <i>Blood</i> , 2019 , 134, 356-356	2.1	1
188	CD40-Activation of Chronic Lymphocytic Leukemia Cells Induces Latent Sensitivity to Fas/TRAIL-Mediated Apoptosis Via a P53-Independent, C-Abl-Dependent Pathway.. <i>Blood</i> , 2004 , 104, 342-342	2.1	1
187	Inhibition of XIAP Enhances Specific Cytotoxic T Lymphocyte (CTL) Killing and CD20-Directed Antibody-Dependent Cellular Cytotoxicity of Chronic Lymphocytic Leukemia B Cells.. <i>Blood</i> , 2004 , 104, 3475-3475	2.1	1
186	Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004 , 104, 4831-4831	2.1	1
185	Pro-Apoptotic Effects on CLL (Chronic Lymphocytic Leukemia) of ABT-737, a Novel Fully Synthetic Bcl-2/Bcl-XL Antagonist.. <i>Blood</i> , 2004 , 104, 952-952	2.1	1
184	ICOS Is Induced by B Cell Receptor Signalling on Chronic Lymphocytic Leukemia B Cells.. <i>Blood</i> , 2004 , 104, 969-969	2.1	1

183	Highly Efficient Gene-Transfer into Chronic Lymphocytic Leukemia Cells Using Adenovirus Type 35 Genetic Vectors.. <i>Blood</i> , 2005 , 106, 2109-2109	2.1	1
182	An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy.. <i>Blood</i> , 2006 , 108, 103-103	2.1	1
181	Combination of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Richter's Syndrome and Fludarabine-Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006 , 108, 2825-2825	2.1	1
180	ZAP-70 Enhances IgM Signaling in Chronic Lymphocytic Leukemia Cells Independent of Its Tyrosine Kinase Activity.. <i>Blood</i> , 2006 , 108, 585-585	2.1	1
179	FCRL2 Expression Is Predictive of IgVH Mutation Status and Clinical Progression in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007 , 110, 488-488	2.1	1
178	Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Aggressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS).. <i>Blood</i> , 2009 , 114, 3443-3443	2.1	1
177	Correlation of Leukemia-Cell Birth Rate Measured by Heavy Water Labeling with Other Prognostic Markers in Early Stage Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 60-60	2.1	1
176	A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL.. <i>Blood</i> , 2010 , 116, 1381-1381	2.1	1
175	Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience. <i>Blood</i> , 2010 , 116, 4638-4638	2.1	2
174	Phenotypic Changes Associated with Acute Reductions In Leukemia Cell Counts In Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Lenalidomide as Initial Therapy. <i>Blood</i> , 2010 , 116, 59-59	2.1	1
173	Agelastatin A (AgA), a Marine Sponge Derived Alkaloid, Inhibits Wnt/Beta-Catenin Signaling and Selectively Induces Apoptosis in Chronic Lymphocytic Leukemia Independently of p53. <i>Blood</i> , 2011 , 118, 1786-1786	2.1	1
172	Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy. <i>Blood</i> , 2011 , 118, 1793-1793	2.1	1
171	Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study). <i>Blood</i> , 2011 , 118, 2859-2859	2.1	1
170	Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect CLL Disease Registry. <i>Blood</i> , 2011 , 118, 2864-2864	2.1	1
169	Subnetwork-Based Analysis of Chronic Lymphocytic Leukemia Identifies Pathways That Associate with Disease Progression,. <i>Blood</i> , 2011 , 118, 3564-3564	2.1	1
168	Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 4591-4591	2.1	1
167	Human ROR1 Activates AKT and Accelerates Leukemia Cell Proliferation. <i>Blood</i> , 2012 , 120, 3872-3872	2.1	1
166	Preclinical Development Of ROR1 Peptide Based Vaccine With Activity Against Chronic Lymphocytic Leukemia In ROR1 Transgenic Mice. <i>Blood</i> , 2013 , 122, 4174-4174	2.1	1

165	Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis. <i>Blood</i> , 2013 , 122, 5299-5299	2.1	1
164	A6 Peptide Is Selectively Cytotoxic For Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2013 , 122, 5303-5303	2.1	1
163	Inhibition of Wnt Signaling By Dimethyl Fumarate Results in in Vitro and in Vivo Clearance of Chronic Lymphocytic Leukemia Cells and Has Additive Activity with Ibrutinib. <i>Blood</i> , 2014 , 124, 4683-4683	2.1	1
162	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 1713-1713	2.1	1
161	Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 2436-2436	2.1	1
160	Plasma B-Cell Maturation Antigen Levels Are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 2931-2931	2.1	1
159	ROR1 Negative Chronic Lymphocytic Leukemia (CLL) Have a Distinctive Gene Expression Signature and May Represent an Indolent-Disease Subtype. <i>Blood</i> , 2015 , 126, 2932-2932	2.1	1
158	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015 , 126, 495-495	2.1	1
157	Cirmtuzumab Targets ROR1 to Inhibit Ibrutinib-Resistant, Wnt5a-Induced Rac1 Activation in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 2034-2034	2.1	1
156	Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 3224-3224	2.1	1
155	Wnt5a Induces Association of ROR1 with 14-3-3 β to Enhance Chemotaxis and Proliferation in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 349-349	2.1	1
154	Gene therapy for cancer. <i>Stem Cells and Development</i> , 1993 , 2, 367-72		1
153	Immunoglobulin Gene Rearrangement and Expression in B-CLL. <i>Leukemia and Lymphoma</i> , 1991 , 5 Suppl 1, 39-45	1.8	1
152	Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia. <i>Cancer Research</i> , 2021 ,	9.6	1
151	Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx). <i>Blood</i> , 2021 , 138, 1548-1548	2.1	1
150	First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study. <i>Blood</i> , 2021 , 138, 68-68	2.1	1
149	Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE). <i>Blood</i> , 2020 , 136, 25-26	2.1	0
148	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.. <i>Leukemia and Lymphoma</i> , 2022 , 1-12	1.8	1

147	Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL. <i>Blood</i> , 2019 , 134, 1755-1755	2.1	1
146	Expression of Ig- κ (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. <i>Blood</i> , 2000 , 95, 2725-2727	2.1	
145	CD38 Compared with ZAP-70 or Immunoglobulin Mutation Status as Predictor of Disease Progression in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004 , 104, 2805-2805	2.1	
144	BAFF Support Survival of Chronic Lymphocytic Leukemia B Cells by a Pathway Independent of Stromal Derived Factor-1 β <i>Blood</i> , 2004 , 104, 1908-1908	2.1	1
143	Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2005 , 106, 2943-2943	2.1	1
142	Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014 , 124, 1998-1998	2.1	
141	Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 2906-2906	2.1	1
140	CCL3 and CCL4 Plasma Levels Correlate with Established Prognostic Markers in Chronic Lymphocytic Leukemia: Towards a Simple, ELISA-Based Assay for Risk Assessment.. <i>Blood</i> , 2009 , 114, 358-358	2.1	1
139	Ad-ISF35 Intratumoral Administration Induces a Bystander Effect and Immune-Mediated Tumor Rejection with a Safe Vector Biodistribution and Toxicology Profile In a NHL Mouse Model.. <i>Blood</i> , 2010 , 116, 1470-1470	2.1	1
138	Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S282-S283	0.7	0
137	Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2021 , 27, 306-313	2.1	0
136	A Phase Ib/II Study of Combined Obinutuzumab and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015 , 126, 4160-4160	2.1	0
135	cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies.. <i>Nature Communications</i> , 2022 , 13, 1698	16.9	0
134	Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study. <i>Blood</i> , 2021 , 138, 2631-2631	2.1	0
133	Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576.. <i>Advances in Hematology</i> , 2022 , 2022, 4450824	1.4	0
132	Immune Therapy for Chronic Lymphocytic Leukemia Induces the Antibody Response Against a Novel Tumor-Associated Antigen, the Orphan Tyrosine Kinase Receptor ROR1.. <i>Blood</i> , 2005 , 106, 2976-2976	2.1	0
131	Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/ β Catenin Signaling in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018 , 132, 2652-2652	2.1	0
130	B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities. <i>HemaSphere</i> , 2022 , 6, e722	0.3	

129	Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, S43	0.7
128	Phase 3 Study of Ibrutinib versus Chlorambucil in Patients \geq 5 Years with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, S45-S46	0.7
127	Cross-Study Multivariable Analysis of the Impact of Adding Rituximab to Venetoclax on the Depth and Durability of Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, S51	0.7
126	Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S274	0.7
125	A Phase 1 Clinical Trial of Cirmtuzumab, a First-in-Class ROR1 Inhibiting Antibody, for the Treatment of Patients with Relapsed or Refractory CLL: Interim Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, S44	0.7
124	**102 Chemoimmunotherapy with Ofatumumab, Fludarabine and Cyclophosphamide (O-FC) in Previously Untreated Patients with Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, S119-S120	0.7
123	5.54 Ad-ISF35 Transduced Autologous Cells Induce Chemosensitization Activity and Complete Responses in Fludarabine-Refractory and/or del(17p)/p53-Defective Chronic Lymphocytic Leukemia Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, S281-S282	0.7
122	5.55 Chronic Lymphocytic Leukemia Associated with Glomerular Disease: A Case Report of Successful Treatment with High-Dose Methyl-Prednisolone in combination with Rituximab Followed by Alemtuzumab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, S282-S283	0.7
121	Poster: CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, S221	0.7
120	Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021 , 138, 3534-3534	2.1
119	Wnt5a Induces ROR1 to Interact Grb2 to Enhance Ras Activation in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021 , 138, 247-247	2.1
118	B Cell-Restricted Depletion of Dnmt3a Activates Notch Signaling and Causes Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021 , 138, 249-249	2.1
117	IKZF3 Overexpression Phenocopies Gain-of-Function Mutation in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 9-9	2.1
116	Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019 , 134, 4274-4274	2.1
115	Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL. <i>Blood</i> , 2019 , 134, 4281-4281	2.1
114	High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019 , 134, 476-476	2.1
113	Tcl-1 Inhibits Nuclear Export of TR3 and Is Highly Expressed in ZAP70-Positive CLL B-Cells.. <i>Blood</i> , 2004 , 104, 967-967	2.1
112	Expression of ZAP-70 in B Cell Chronic Lymphocytic Leukemia Is Associated with a Greater Capacity To Activate NF κ B Following Ligation of Surface Immunoglobulin.. <i>Blood</i> , 2004 , 104, 2812-2812	2.1

- 111 A Phase I/II Trial of Xcellerated T Cells in Patients with Chronic Lymphocytic Leukemia.. *Blood*, **2004**, 104, 2508-2508 2.1
- 110 Rituximab and High Dose Methylprednisolone (HDMP) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.. *Blood*, **2004**, 104, 2518-2518 2.1
- 109 Nurse-like Cells in Chronic Lymphocytic Leukemia (CLL) Express Both BAFF and APRIL that Protect CLL B Cells from Spontaneous Apoptosis by Paracrine Manner.. *Blood*, **2004**, 104, 965-965 2.1
- 108 Inhibition of XIAP Renders Newly CD40-Activated Chronic Lymphocytic Leukemia Cells Sensitive to Fas (CD95) Mediated Apoptosis.. *Blood*, **2004**, 104, 3474-3474 2.1
- 107 ZAP-70 Expressed in CLL Is an Hsp90 Client Protein and Its Level of Expression Can Be Downregulated by Specific Hsp90 Inhibitors.. *Blood*, **2004**, 104, 2803-2803 2.1
- 106 Chronic Lymphocytic Leukemia Cells May Become Less Dependent on Nurse-Like Cells during Later Stages of Disease.. *Blood*, **2004**, 104, 4805-4805 2.1
- 105 R- β -Gossypol (AT101) Binds to Bcl-2 Family Proteins and Induces Apoptosis in CLL.. *Blood*, **2005**, 106, 2978-2978 2.1
- 104 Activation of AKT and Enhanced Resistance to Apoptosis Induced by Surface IgM Ligation in ZAP-70-Positive Chronic Lymphocytic Leukemia B Cells.. *Blood*, **2005**, 106, 2940-2940 2.1
- 103 Differential Expression Profile of the Proteome and Transcriptome in Aggressive and Indolent Chronic Lymphocytic Leukemia.. *Blood*, **2005**, 106, 2101-2101 2.1
- 102 BAFF and APRIL Protect CLL B Cells from Apoptosis through Activation of NF- κ B Canonical Pathway.. *Blood*, **2005**, 106, 179-179 2.1
- 101 Rituximab and High Dose Methylprednisolone (HDMP) as a First Line Treatment for Patients with Chronic Lymphocytic Leukemia.. *Blood*, **2005**, 106, 2969-2969 2.1
- 100 Expression of Lymphocyte Activation Gene 3 (LAG-3/CD223) by Chronic Lymphocytic Leukemia B Cells.. *Blood*, **2005**, 106, 2952-2952 2.1
- 99 A Bioinformatic Approach to CLL IGHV Sequence Analysis Identifies Extensive Ig Sequence Archetypes among Both Mutated and Unmutated Sequences.. *Blood*, **2005**, 106, 176-176 2.1
- 98 Restricted Pairing of Immunoglobulin Heavy and Light Chains Expressed by Chronic Lymphocytic Leukemia B Cells Is Predicated on the Heavy Chain CDR3.. *Blood*, **2005**, 106, 2094-2094 2.1
- 97 Elevated expression of PDE7B in Chronic Lymphocytic Leukemia. *FASEB Journal*, **2006**, 20, LB120 0.9
- 96 Expression of ZAP-70 in Chronic Lymphocytic Leukemia Cells Enhances CD79b Phosphorylation Following Surface IgM Ligation.. *Blood*, **2006**, 108, 2799-2799 2.1
- 95 Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.. *Blood*, **2006**, 108, 2774-2774 2.1
- 94 Chronic Lymphocytic Leukemia Cells Can Induce Monocytes to Express High Levels of BAFF and Assume Properties of Nurse-like Cells In Vitro.. *Blood*, **2006**, 108, 588-588 2.1

93	Ethacrynic Acid Can Inhibit Wnt/ β Catenin Signaling and Induce Apoptosis in Chronic Lymphocytic Leukemia Cells.. <i>Blood</i> , 2006 , 108, 2099-2099	2.1
92	Chronic Lymphocytic Leukemia Cells Have Increased Expression of Cyclic Nucleotide Phosphodiesterase 7B, Which May Serve as Disease-Specific Therapeutic Target.. <i>Blood</i> , 2006 , 108, 2802-2802	2.1
91	Expression of ROR1 in Chronic Lymphocytic Leukemia Cells Enhances Cells Survival by Wnt5a Signaling.. <i>Blood</i> , 2007 , 110, 340-340	2.1
90	BAFF Accelerates Development of Chronic Lymphocytic Leukemia in TCL1 Transgenic Mice.. <i>Blood</i> , 2007 , 110, 1117-1117	2.1
89	TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP-70.. <i>Blood</i> , 2007 , 110, 2068-2068	2.1
88	Autoantibodies Against p53 Are Associated with p17 Deletions in CLL.. <i>Blood</i> , 2007 , 110, 2066-2066	2.1
87	Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L.. <i>Blood</i> , 2007 , 110, 740-740	2.1
86	Chronic Lymphocytic Leukemia Cells Produce a Soluble Factor(s) That Can Induce CD14+ Blood Mononuclear Cells To Assume Properties of Nurselike Cells In Vitro.. <i>Blood</i> , 2007 , 110, 1136-1136	2.1
85	High Level Phosphatase Activity Revealed in Chronic Lymphocytic Leukemia Cells That Use Mutated Immunoglobulin Heavy Chain Variable Region Genes and Lack High-Level Expression of the Zeta-Associated Protein 70 (ZAP-70).. <i>Blood</i> , 2007 , 110, 743-743	2.1
84	An International Multi-Center Study To Define the Application of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia (MILE Study): Analysis of Completed Stage I with 2030 Patients Achieved a 95.4% Accuracy.. <i>Blood</i> , 2007 , 110, 3169-3169	2.1
83	KDE Analysis in Chronic Lymphocytic Leukemia Patients with B Cells Expressing IGHV3-21 and Discordant Mutational Status between Heavy and Light Chain.. <i>Blood</i> , 2007 , 110, 1127-1127	2.1
82	Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018 , 132, 4415-4415	2.1
81	Single Cell Transcriptomic Characterization of the Immune Microenvironment in Naturally Progressing Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018 , 132, 3112-3112	2.1
80	ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018 , 132, 1853-1853	2.1
79	A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions. <i>Blood</i> , 2018 , 132, 1863-1863	2.1
78	Activation of NF-Kappa B-p62-NRF2 Signaling Supports the Survival of CLL Cells That Express High Levels of ROR1. <i>Blood</i> , 2018 , 132, 3122-3122	2.1
77	B-Cell Receptor Signaling Drives Glycolysis in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2018 , 132, 3121-3121	2.1
76	Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels. <i>Blood</i> , 2018 , 132, 1864-1864	2.1

- 75 Wnt5a Induces Association of ROR1 with Ca²⁺/Calmodulin-Dependent Protein Kinase II and ROR1-Dependent Calcium Influx in Chronic Lymphocytic Leukemia. *Blood*, **2018**, 132, 1846-1846 2.1
- 74 Tecfidera Modulates Activation of Malignant B-Cells: Correlative Analysis from a Phase 1 Clinical Trial in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2018**, 132, 3143-3143 2.1
- 73 Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. *Blood*, **2018**, 132, 4759-4759 2.1
- 72 Dynamics Changes in CCL3 and CCL4 Plasma Chemokine Levels in Patients with Chronic Lymphocytic Leukemia (CLL) Managed with Observation. *Blood*, **2014**, 124, 5640-5640 2.1
- 71 A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. *Blood*, **2014**, 124, 1976-1976 2.1
- 70 Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry. *Blood*, **2014**, 124, 4672-4672 2.1
- 69 Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL Cohort Study. *Blood*, **2015**, 126, 3284-3284 2.1
- 68 Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL Registry. *Blood*, **2015**, 126, 4483-4483 2.1
- 67 Structural Features of ROR1 Required for Complexing with ROR2 and Enhancing Chemokine-Induced Migration and Leukemia-Cell Proliferation, Which Can be Blocked By the Anti-ROR1 Mab Cirmtuzumab (UC-961). *Blood*, **2015**, 126, 1741-1741 2.1
- 66 Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL. *Blood*, **2015**, 126, 4153-4153 2.1
- 65 Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL Registry. *Blood*, **2015**, 126, 5270-5270 2.1
- 64 Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL. *Blood*, **2015**, 126, 1747-1747 2.1
- 63 Active Immune Gene Therapy Using ISF35: Responses Associated with Priming for Death Receptor-Induced Apoptosis and Sensitivity to Fludarabine in Patients with CLL and Del 17p. *Blood*, **2008**, 112, 3530-3530 2.1
- 62 CLLU1, a Novel Molecular Marker for Minimal Residual Disease Monitoring in Chronic Lymphocytic Leukemia. *Blood*, **2008**, 112, 3158-3158 2.1
- 61 Predicting Time to Initial Treatment in Early Stage CLL - Integration of Classical and Novel Prognostic Factors.. *Blood*, **2008**, 112, 2093-2093 2.1
- 60 The Relative Dependency of Chronic Lymphocytic Leukemia (CLL) Cells on Nurselike Cells for in Vitro Survival Is Associated with Overall Survival in Previously Untreated CLL Patients. *Blood*, **2008**, 112, 4169-4169 2.1
- 59 Early Events in the Clonal Evolution in Patients with Chronic Lymphocytic Leukemia Carrying TP53 Mutations and 17p Deletion. *Blood*, **2008**, 112, 4165-4165 2.1
- 58 A Phase I Study of Immune Gene Therapy for Patients with CLL Using Intranodal Injection of ISF35, a Membrane-Stable CD40 Binding Protein.. *Blood*, **2008**, 112, 2100-2100 2.1

57	Chronic Lymphocytic Leukemia Cells Promote Increased BAFF Expression in Monocytes Partially through TNF-Alpha Leading to Increased CLL Cell Survival. <i>Blood</i> , 2008 , 112, 3154-3154	2.1
56	Interactome-Based Molecular Prognosis of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008 , 112, 545-545	2.1
55	Platinum-Based Compounds Induce Expression of p73 and Restores Drug- Sensitivity in p53 Dysfunctional Chronic Lymphocytic Leukemia (CLL) Cells.. <i>Blood</i> , 2008 , 112, 2102-2102	2.1
54	Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium.. <i>Blood</i> , 2008 , 112, 1067-1067	2.1
53	Detection of Minimal Residual Disease in Chronic Lymphocytic Leukemia with Monoclonal Antibodies Specific for CD5, CD10, CD19, and ROR1.. <i>Blood</i> , 2008 , 112, 2079-2079	2.1
52	Plasma Alemtuzumab Levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease.. <i>Blood</i> , 2008 , 112, 2109-2109	2.1
51	Protein kinase A and Epac (Exchange Protein Activated by cAMP) are Pro-and Anti-Apoptotic Mediators, respectively, in Chronic Lymphocytic Leukemia. <i>FASEB Journal</i> , 2009 , 23, 761.11	0.9
50	Comparison of in Vitro Apoptotic Response of Chronic Lymphocytic Leukemia (CLL) Cells to Bcl-2 Antagonist ABT-737 and IAP Antagonist BV6.. <i>Blood</i> , 2009 , 114, 4386-4386	2.1
49	B Cell Activating Factor and c-Myc Regulate the Progression of Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 359-359	2.1
48	Ad-ISF35-Transduced Autologous Cells Promote in Vitro and In Vivo Chemosensitization to FCR in Patients with Del(17p) / P53 Defective Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 376-376	2.1
47	Karyotype Results From CpG Oligodeoxynucleotide Stimulated Chronic Lymphocytic Leukemia (CLL) Cultures Are Consistent Among Laboratories: a CLL Research Consortium (CRC) Study.. <i>Blood</i> , 2009 , 114, 1614-1614	2.1
46	Analysis of the Serum Free Light Chain Ratio and Its Prognostic Value in a Cohort of Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 2631-2631	2.1
45	Influence of Mir-155 On B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 2343-2343	2.1
44	Single Cell Profiling of B Cell Receptor Signaling and Apoptosis Networks in Chronic Lymphocytic Leukemia: Association with in Vitro Sensitivity to Fludarabine Monophosphate (F-ara-A).. <i>Blood</i> , 2009 , 114, 1263-1263	2.1
43	Lenalidomide Administered for the Initial Treatment of Chronic Lymphocytic Leukemia (CLL) Patients- In Vivo Modulation of the Leukemia Cell Surface Phenotype and Association with Tumor Flare Reaction (TFR).. <i>Blood</i> , 2009 , 114, 3440-3440	2.1
42	CD137/4-1BB Is Inducibly Expressed On CLL B Cells through CD40 Signaling.. <i>Blood</i> , 2009 , 114, 1266-1266.1	2.1
41	Targeting phosphodiesterase 7B and exchange protein directly activated by cAMP-1 in chronic lymphocytic leukemia. <i>FASEB Journal</i> , 2010 , 24, 965.2	0.9
40	ROR1 Is Expressed on the Surface of Non-Neoplastic Human B-Lymphocyte Precursors (Hematogones) and on a Subset of B Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010 , 116, 2735-2735	2.1

- 39 Longitudinal Genomic Analyses In Chronic Lymphocytic Leukemia (CLL) Patients Reveal Clonal Relationship and Genomic Evolution In Disease Progression and After Therapy. *Blood*, **2010**, 116, 3605-3605^{2,1}
- 38 Ad-ISF35- Transduced Autologous Cells Promote In Vitro and In Vivo Chemosensitization to FCR and Durable Complete Responses In Patients with Del(17p)/P53 Defective Chronic Lymphocytic Leukemia.. *Blood*, **2010**, 116, 1472-1472 2.1
- 37 The Kinase Inhibitor Sorafenib Can Disrupt the Survival Support Provided by the Microenvironment and Induce Apoptosis of Chronic Lymphocytic Leukemia Cells. *Blood*, **2010**, 116, 47-47 2.1
- 36 CXCL12 Enhances Survival of Chronic Lymphocytic Leukemia Cells Via a RAF-Dependent Pathway That Can Be Inhibited by Sorafenib. *Blood*, **2010**, 116, 2445-2445 2.1
- 35 Immune Gene Therapy for Patients with CLL Using Repeat Dose Intranodal Injection of Ad-ISF35, a Replication Incompetent Vector Expressing a Membrane-Stable CD40 Binding Protein.. *Blood*, **2010**, 116, 1476-1476 2.1
- 34 Improved Outcome of CLL Patients with Leukemic Clones Expressing Mutated IGHV May Not Be Due to An Inability to Bind (auto)Antigen In Vivo. *Blood*, **2010**, 116, 2441-2441 2.1
- 33 Mir-155 Contributed to Chronic Lymphocytic Leukemia Survival by Modulation of BCR-Signalling. *Blood*, **2011**, 118, 620-620 2.1
- 32 Targeting of Chronic Lymphocytic Leukemia B Cells with a Novel Monoclonal Antibody to ROR1. *Blood*, **2011**, 118, 984-984 2.1
- 31 Relative Prognostic Significance of ZAP-70 and IGHV1-69 Expression in Chronic Lymphocytic Leukemia,. *Blood*, **2011**, 118, 3891-3891 2.1
- 30 Low Expression of ROR1 on Chronic Lymphocytic Leukemia Is Associated with Other Atypical Findings. *Blood*, **2011**, 118, 4588-4588 2.1
- 29 ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice,. *Blood*, **2011**, 118, 3905-3905 2.1
- 28 Lenalidomide Inhibits Proliferation of Chronic Lymphocytic Leukemia Cells in Vitro. *Blood*, **2011**, 118, 1775-1775 2.1
- 27 Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,. *Blood*, **2011**, 118, 3885-3885^{2,1}
- 26 MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene. *Blood*, **2011**, 118, 2846-2846 2.1
- 25 Highly Specific Inhibitor for Syk Induces Chronic Lymphocytic Leukemia Cell Apoptosis,. *Blood*, **2011**, 118, 3875-3875 2.1
- 24 Heat Shock Protein 90 (Hsp90) Activity Status Is An Independent Prognostic Marker in Chronic Lymphocytic Leukemia (CLL) and Correlates with IgVH Mutational Status, ZAP-70 Expression and Time to First Treatment. *Blood*, **2011**, 118, 2544-2544 2.1
- 23 Improved Outcome in Unrelated Donor Recipients After Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Advanced Relapse / Refractory Chronic Lymphocytic Leukemia. *Blood*, **2011**, 118, 4474-4474 2.1
- 22 In Vitro Propagation of Mesenchymal Stromal Cells From Marrow Aspirates of Patients with Chronic Lymphocytic Leukemia Is Dependent Upon Physiologic Oxygen Tension. *Blood*, **2011**, 118, 2839-2839^{2,1}

21	Increased Activity of Aldehyde Dehydrogenase, a Stem/Progenitor Cell Marker, in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2011 , 118, 3867-3867	2.1
20	Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011 , 118, 1423-1428	2.1
19	Eradication of Minimal Residual Disease Using Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 2866-2866	2.1
18	Efficient Gene Delivery to Chronic Lymphocytic Leukemia (CLL) Cells with Microbubbles Bearing ROR1 Antibody. <i>Blood</i> , 2011 , 118, 2857-2857	2.1
17	Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 1785-1785	2.1
16	A Monoclonal Antibody Specifically Targeting CD44 Inhibits B-Cell Chronic Lymphocytic Leukemia Cell Survival In Vitro and In Vivo. <i>Blood</i> , 2011 , 118, 927-927	2.1
15	The Target Genes and Prognostic Significance of Mir-150 in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 3859-3859	2.1
14	Chemical Biology Strategy Reveals Cell Lineage- and Cell Differentiation-Specific Small Molecule Inhibitors of NF- κ B.. <i>Blood</i> , 2012 , 120, 2421-2421	2.1
13	Selective Clearance of Chronic Lymphocytic Leukemia Cells in Vivo Following Treatment with UC99961, an Anti-ROR1 Monoclonal Antibody. <i>Blood</i> , 2012 , 120, 3886-3886	2.1
12	Genomic Analysis of Serial Chronic Lymphocytic Leukemia Samples Suggests That Epigenetic Changes, Rather Than Clonal Evolution, May Drive the Progression of This Leukemia. <i>Blood</i> , 2012 , 120, 4563-4563	2.1
11	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. <i>Blood</i> , 2012 , 120, 3865-3865	2.1
10	BMS-936564 (MDX1338): A Fully Human Anti-CXCR4 Antibody Induces Apoptosis in an in Vitro Model of Stromal Leukemia Cell Interaction for Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012 , 120, 2887-2887	2.1
9	Variation in health-related quality of life (HRQOL) by line of therapy, age, and gender among patients with chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7086-7086	2.1
8	Targeting Of Chronic Lymphocytic Leukemia B Cells With a Humanized Monoclonal Antibody Specific For ROR1. <i>Blood</i> , 2013 , 122, 2873-2873	2.1
7	A Cyclopropane-Derived Stable Analog Of Fd-895 Induces Apoptosis and Inhibition Of mRNA Splicing In Lymphoma and Chronic Lymphocytic Leukemia: A Novel Therapeutic Approach. <i>Blood</i> , 2013 , 122, 2884-2884	2.1
6	Allele-Specific Loss Of The Mir-15a/16-1 Cluster Correlates With ZAP70 Expression In CLL Patients With 13q Deletion. <i>Blood</i> , 2013 , 122, 3753-3753	2.1
5	Lenalidomide Inhibits Proliferation Of Chronic Lymphocytic Leukemia Cells Via a Cereblon/p21WAF1/Cip1-Dependent Mechanism. <i>Blood</i> , 2013 , 122, 4139-4139	2.1
4	Targeting Chronic Lymphocytic Leukemia With DNA Nanoparticles. <i>Blood</i> , 2013 , 122, 1623-1623	2.1

- 3 Inhibition Of Wnt Signaling In Chronic Lymphocytic Leukemia Has Synergistic Cytotoxicity With Ibrutinib. *Blood*, **2013**, 122, 5306-5306 2.1
- 2 Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia. *Blood*, **2013**, 122, 1626-1626 2.1
- 1 Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility. *Blood*, **2013**, 122, 4159-4159 2.1